IBYME   02675
INSTITUTO DE BIOLOGIA Y MEDICINA EXPERIMENTAL
Unidad Ejecutora - UE
artículos
Título:
Clinical relevance of galectin-1 expression in non-small cell lung cancer patients
Autor/es:
CARLINI MJ; ROITMAN P; NUÑEZ ; PALLOTA G; BOGGIO ; SMITH; SALATINO M; BAL DE KIER JOFFÉ E; RABINOVICH GA; PURICELLI L
Revista:
LUNG CANCER
Editorial:
ELSEVIER IRELAND LTD
Referencias:
Lugar: Amsterdam; Año: 2014 vol. 84 p. 73 - 78
ISSN:
0169-5002
Resumen:
BACKGROUND: Identification of biomarkers in lung cancer, a leading cause of cancerrelated
mortality, has a meaningful clinical relevance in the quest of novel prognostic
factors and therapeutic targets. The glycan-binding protein galectin-1 (Gal-1) modulates
tumor progression by mediating cell-cell and cell-extracellular matrix interactions, as well
as angiogenesis and tumor immune-escape. Previous works reported the expression of Gal-
1 in lung cancer, although its clinical significance remains uncertain. OBJECTIVE: To
assess the clinicopathologic relevance and prognostic value of Gal-1 expression in a cohort
of 103 Stage I-III non-small cell lung cancer (NSCLC) patients. METHODS: Gal-1
expression was determined by immunohistochemistry in tumor tissue samples. The
percentage of immunoreactive tumor cells and stroma, as well as the presence of blood
vessels with positively stained endothelium in the intratumoraltumor and peritumoral
areassurrounding normal tissue, were recorded. Results were correlated with the
clinicopathologic factors of the patients (Spearman´s rank correlation coefficient, chi-square
test) and overall survival by univariate (Kaplan Meier) and multivariate analyses (Cox
regression hazard model). RESULTS: We did not observe significant associations between
Gal-1 expression and relevant clinicopathologic features at diagnosis of NSCLC. However,
Kaplan Meier analysis revealed a significant association between Gal-1 expression and
overall survival, when Gal-1 expression was analyzed on tumor cells alone (?tumor cell
percentage?) or when an integrated score accounting for tumor cell as well as stromal
expression of Gal-1 (?total score?) was assessed. Patients showing high Gal-1 expression
evidenced a poorer clinical outcome. Furthermore, ?total score? remained significantly
associated with survival by multivariate Cox regression analysis in the whole cohort of
patients, even when controlling for the classical predictors and prognostic factors of
NSCLC. CONCLUSION: We conclude that Gal-1 expression may be a useful biomarker
for better prediction of the clinical outcome and management of NSCLC patients.